Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 27 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Adstiladrin for high-grade, BCG unresponsive non-muscle-invasive bladder cancer	Adstiladrin (Nadofaragene firadenovec; rAd-IFN/Syn3; Instiladrin)	Bladder cancer	Urological Cancer	2019	View \| Download
Atezolizumab for muscle-invasive urothelial carcinoma –adjuvant	Atezolizumab (Tecentriq; MPDL3280A)	Bladder cancer	Urological Cancer	2019	View \| Download
Atezolizumab in combination with platinum-based chemotherapy for untreated locally advanced or metastatic urothelial cancer – first line	Atezolizumab (Tecentriq; MPDL3280A)	Urothelial cancer	Urological Cancer	2020	View \| Download
Avatrombopag for chemotherapy induced thrombocytopenia in patients with nonhaematological cancers	Avatrombopag (Doptelet; E5501; avatrombopag maleate)	Chemotherapy-induced thrombocytopenia	Female Reproductive Cancer , Haematology , Lung and Respiratory Cancer , Toxicology , Urological Cancer	2020	View \| Download
Avelumab in addition to best supportive care for locally advanced or metastatic urothelial cancer	Avelumab (Bavencio; MSB-0010718C)	Bladder cancer	Urological Cancer	2019	View \| Download
Durvalumab (Imfinzi) for locally advanced or metastatic urothelial bladder cancer – first line	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Bladder cancer	Urological Cancer	2017	View \| Download
Durvalumab and enfortumab vedotin with or without tremelimumab for muscle-invasive bladder cancer	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Enfortumab vedotin (ASG-22ME; Padcev) , Tremelimumab (CP-675206; CP-675 206)	Bladder cancer	Urological Cancer	2024	View \| Download
Durvalumab in combination with tremelimumab and chemotherapy for unresectable, locally advanced or metastatic urothelial cancer	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Tremelimumab (CP-675206; CP-675 206)	Bladder cancer	Urological Cancer	2020	View \| Download
Durvalumab in combination with Tremelimumab for locally advanced or metastatic urothelial bladder cancer – first line	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Tremelimumab (CP-675206; CP-675 206)	Bladder cancer	Urological Cancer	2017	View \| Download
Durvalumab with Bacillus Calmette-Guerin for treating non-muscle invasive bladder cancer	Bacillus Calmette-Guerin (BCG; BCG Tokyo-172; OncoTICE) , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Bladder cancer	Urological Cancer	2022	View \| Download